Landmark `Consensus Statement' On Biomedical Research Support Is Greeted By Mixed Reactions

Support Is Greeted By Mixed Reactions Author: BARBARA SPECTOR, pp.1 Date: May 30,1994 Some observers regard the plea to Congress, signed by 156 organizations, as an urgently needed document, but others see flaws in it A "consensus statement" advocating increased medical research funding by the United States government--endorsed by 156 institutions, associations, and companies and presented to Congress earlier this month --will b

Written byBarbara Spector
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Support Is Greeted By Mixed Reactions Author: BARBARA SPECTOR, pp.1
Date: May 30,1994

Some observers regard the plea to Congress, signed by 156 organizations, as an urgently needed document, but others see flaws in it

A "consensus statement" advocating increased medical research funding by the United States government--endorsed by 156 institutions, associations, and companies and presented to Congress earlier this month --will be a significant addition to the national health-care-reform debate, say those who have signed the document. The signatories say its message will be particularly effective because such declarations are rarely made jointly by diverse sectors of the research community.

Some health-policy specialists agree with this assessment of the statement's importance, predicting that its language will likely appeal to President Clinton. But as the declaration was being delivered to members of Congress, objections to it were coming from several quarters.

A number of long-time health-policy watchers, for example, believe ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies